Á¦42Â÷ ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãá°èÇмú´ëȸ 밎 Á¦16Â÷ ±¹Á¦½ÉÆ÷Áö¾ö (KCR2022) 3ÀÏÂ÷ : 2022-05-21±³À°ÀÏÀÚ : 2022-05-21
±³À°Àå¼Ò : µå·¡°ï½ÃƼ (¿Â¶óÀÎ-¿ÀÇÁ¶óÀÎ º´Çà)
±³À°ÁÖÁ¦ :
Á¦42Â÷ ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãá°èÇмú´ëȸ 밎 Á¦16Â÷ ±¹Á¦½ÉÆ÷Áö¾ö (KCR2022) 3ÀÏÂ÷ÁÖÃÖ±â°ü : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ
´ã´çÀÚ : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ
¿¬¶ôó : 02-794-2630
À̸ÞÀÏ :
webmaster@rheum.or.kr ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Á¤Çü¿Ü°ú, ¿µ»óÀÇÇаú, ÀçÈ°ÀÇÇаú, °¡Á¤ÀÇÇаú
Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 18 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 120,000¿ø
ºñ°í ȸ¿ø Àü¹®ÀÇ 120,000¿ø, ȸ¿ø Àü°øÀÇ 60,000¿ø ºñȸ¿ø Àü¹®ÀÇ 150,000¿ø, ºñȸ¿ø Àü°øÀÇ 80,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-21 ROOM A 08:00~08:40 Biosimilar: Past, present and future È«½ÂÀç(°æÈñÀÇ´ë)
±³À°½Ã°£ 05-21 ROOM A 09:00~10:00 The future of rheumatology Antony Rosen(Johns Hopkins, USA)
±³À°½Ã°£ 05-21 ROOM A 10:30~11:00 Hype and truth - treatment paradigm of osteoarthritis David Hunter(Univ. of Sydney, Australia)
±³À°½Ã°£ 05-21 ROOM A 11:00~11:30 Addicted to preion, medical abuse of osteoarthritis Yuqing Zhang(Massachusetts General Hosp., USA)
±³À°½Ã°£ 05-21 ROOM A 11:30~12:00 Use or abuse? APM for degenerative meniscus in osteoarthritis ±èÇö¾Æ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 05-21 ROOM A 12:00~12:40 The role of IL-17A in axial spondyloarthritis and axial PsA Matthew Brown(Kings College London, UK)
±³À°½Ã°£ 05-21 ROOM A 13:00~13:30 Synovial macrophages as gatekeepers of inflammation Gerhard Krönke(Alexander Univ. Erlangen, Germany)
±³À°½Ã°£ 05-21 ROOM A 13:30~14:00 Notch signalling drives synovial fibroblast identity and arthritis pathology Soumya Raychaudhuri(Brigham and Women¡¯s Hosp. and Harvard Medical School, USA)
±³À°½Ã°£ 05-21 ROOM A 14:00~14:30 Roles of stromal cells and potential significance for future therapy in RA ÀÌ»óÀÏ(°æ»óÀÇ´ë)
±³À°½Ã°£ 05-21 ROOM A 15:30~16:00 Update in the pathogenesis of systemic sclerosis Christopher Denton(Royal Free Hosp., UK)
±³À°½Ã°£ 05-21 ROOM A 16:00~16:30 Update in interstitial lung disease in SSc Oliver Distler(Univ. Hosp. Zurich, Switzerland)
±³À°½Ã°£ 05-21 ROOM A 16:30~17:00 Update in pulmonary arterial hypertension in SSc ÀÌÀººÀ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-21 ROOM B 08:00~08:40 IL-17 inhibition in spondyloarthritis: The efficacy of Ixekizumab and clinical relevance ÀÌ¿¬¾Æ(°æÈñÀÇ´ë)
±³À°½Ã°£ 05-21 ROOM B 10:30~12:00 Free Paper Session – Spondyloarthritis ±¸¿¬(¹ßÇ¥ ¼¼¼Ç)
±³À°½Ã°£ 05-21 ROOM B 12:00~12:40 Denosumab key clinical questions ±è¼º¼ö(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05-21 ROOM B 13:00~13:30 Anabolic therapy for osteoporosis ±èÇÏ¿µ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05-21 ROOM B 13:30~14:00 Ideal sequential therapy in osteoporosis management ±è°æ¹Î(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-21 ROOM B 14:00~14:30 Prevention and treatment of fracture in RA ¹ÎÁرâ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 05-21 ROOM B 15:30~17:00 Free Paper Session – Rheumatoid Arthritis Basic Research ±¸¿¬(¹ßÇ¥ ¼¼¼Ç)
±³À°½Ã°£ 05-21 ROOM C 08:00~08:40 Long-lasting Golimumab in AS: Learnings real-world evidence ±¸º»»ê(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 05-21 ROOM C 10:30~12:00 Free Paper Session – Systemic Lupus Erythematosus ±¸¿¬(¹ßÇ¥ ¼¼¼Ç)
±³À°½Ã°£ 05-21 ROOM C 12:00~12:40 Tacrolimus in rhematoid arthritis ÃÖÂù¹ü(ÇѾçÀÇ´ë)
±³À°½Ã°£ 05-21 ROOM C 13:00~14:30 Free Paper Session – Vasculitis and Metabolic Bone Disease ±¸¿¬(¹ßÇ¥ ¼¼¼Ç)
±³À°½Ã°£ 05-21 ROOM C 15:30~16:00 Rheumatic diseases and KCD 8th revision ±è¼®ÀÏ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 05-21 ROOM C 16:00~16:30 Principles and future prospects of insurance benefits in rheumatoid diseases ¼±âÇö(°Ç°º¸Çè½É»çÆò°¡¿ø)
±³À°½Ã°£ 05-21 ROOM C 16:30~17:00 Insurance guideline and tips for treatment of rheumatic disease È«½ÂÀç(°æÈñÀÇ´ë)